Andrea Paes de Lima

Andrea Paes de Lima

Auto-generated profile, based on publicly available information

Andrea Paes de Lima

Programa Franco-argentino de Estudio del Cáncer de Páncreas, Buenos Aires, Argentina; Departamento de Patología, Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2018 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FPFabián Pitoia
Fabián Pitoia
FJFernando Jerkovich
Fernando Jerkovich
CUCarolina Urciuoli
Carolina Urciuoli
FFFlorencia Falcón
Florencia Falcón
ALAndrea Páes de Lima
Andrea Páes de Lima
Keywords Risk of recurrence; response to therapy; differentiated thyroid cancer; historic histopathologic review

1 January 2025 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MFMaría Gabriela García Falcone
María Gabriela García Falcone
SASantiago Gonzalez Abbati
Santiago Gonzalez Abbati
SSSoledad Sosa
Soledad Sosa
ALAndrea Paes de Lima
Andrea Paes de Lima
FPFlorencia Peralta
Florencia Peralta
KDKarina Danilowicz
Karina Danilowicz
Doubleor multiple adenomas are rare, and synchronous secretory pituitary adenomas are rarer still. We report a case of a 30-year-old woman with a 6-year history of amenorrhea and occasional galactorrhoea. She presented with headaches, weight gain, subtle acromegalic features, new-onset hypertension and diabetes. Workup confirmed acromegaly and hyperprolactinemia. Preoperative magnetic resonance imaging of the pituitary demonstrated two noncontiguous microadenomas. Two distinct tumors were resected through a transsphenoidal approach. Immunohistochemical analysis of each separated adenoma confirmed the diagnosis of acromegaly [...] Abstract Doubleor multiple adenomas are rare, and synchronous secretory pituitary adenomas are rarer still. We report a case of a 30-year-old woman with a 6-year history of amenorrhea and occasional galactorrhoea. She presented with headaches, weight gain, subtle acromegalic features, new-onset hypertension and diabetes. Workup confirmed acromegaly and hyperprolactinemia. Preoperative magnetic resonance imaging of the pituitary demonstrated two noncontiguous microadenomas. Two distinct tumors were resected through a transsphenoidal approach. Immunohistochemical analysis of each separated adenoma confirmed the diagnosis of acromegaly

15 February 2021 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FBFernanda Bueno
Fernanda Bueno
EAErika Abelleira
Erika Abelleira
FSFlorencia von Stecher
Florencia von Stecher
ALAndrea Paes de Lima
Andrea Paes de Lima
FPFabián Pitoia
Fabián Pitoia
Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.

16 July 2026 in Translational Oncology
Verified
Journal Article
Open access
ECEduardo Chuluyan
Eduardo Chuluyan
DGDaniel Grasso
Daniel Grasso
APAnalia Pasqua
Analia Pasqua
CRCarla Remolins
Carla Remolins
ALAndrea Paes de Lima
Andrea Paes de Lima
JIJuan Iovanna
Juan Iovanna
Pancreatic ductal adenocarcinoma (PDAC) remains clinically managed largely through anatomical stage and performance status, despite major inter-patient heterogeneity and dynamic pathway adaptation during progression. In this review, we propose a hypothesis-generating, stage-aware framework in which clinical stage and established molecular subtypes are considered complementary rather than competing stratification axes. Stage-resolved transcriptomic modeling identified a directional separation across up-front resectable, borderline/locally advanced, primary metastatic and liver metastatic samples, with PC1 explaining 51.1% of the variance and separating early from metastatic states, whereas PC2 explained 30.2% and captured immune/stromal remodeling. We interpret these observations cautiously as pathway-level signals that require functional and clinical validation, not as an established biological paradigm. The model suggests a transition from MAPK-enriched, proliferative and partially immune-competent tumors toward metastatic ecosystems characterized by PI3K-AKT-mTOR engagement, MYC amplification, mitochondrial metabolism, proteostasis support and immune exclusion. We further distinguish approved standards, negative clinical experiences, early clinical signals and preclinical hypotheses. The central conclusion is that PDAC therapeutic stratification should integrate stage, molecular subtype, treatment line, tissue context and evidence level before pathway-directed interventions are clinically prioritized. Accordingly, this review should be read as a translational prioritization framework rather than as a treatment algorithm: it organizes where pathway-directed hypotheses are most biologically plausible, where they are clinically supported, and where they remain insufficiently validated for routine decision-making.